Trials
2 active
2 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 1 mg, 4mg, and 10 mg strength capsules, intended for oral administration once daily.”In the company’s words, NCT06299839 on ClinicalTrials.gov
- Tested for
- NF1 Mutation (2 trials), RAS Mutation, RAF Mutation, Advanced Solid Tumors, Neurofibroma Plexiform, Neurofibroma, Plexiform, Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Neurofibromatosis Type 1 (NF1)
- Main trialPhase 1
- “The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), or rapidly accelerated fibrosarcoma (RAF) mutations. The main questions it aims to answer are: * How well participants are able tolerate different doses of PAS-004, and * What side effects PAS-004 might have. Study participants will have regular visits to the study doctor and be asked to have tests and exams done to check on their health and safety. Everyone participating in the study will take PAS-004 by mouth as a single dose,…”In the company’s words, NCT06299839 on ClinicalTrials.gov
Other drugs for NF1 Mutation
- PembrolizumabMerck & Co. · Phase 3
- CemiplimabRegeneron · Phase 3
- DarovasertibIDEAYA Biosciences · Phase 3
- FianlimabRegeneron · Phase 3
- BCD-217Biocad · Phase 3
- ISCIB1+Scancell Ltd · Phase 3
Coming up2
- Sep 2027Phase 1 trial completes · ClinicalTrials.gov
- Feb 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Sep 2027 | PAS-004 in Patients With Advanced Solid Tumors | |
| Phase 1Recruiting | Feb 2028 | PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026